Chemotherapy-induced neutropenia
Adult: To reduce incidence of infection in patients with non-myeloid malignancies: 6 mg as a single dose for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.
Indications and Dosage
Subcutaneous
Chemotherapy-induced neutropenia Adult: To reduce incidence of infection in patients with non-myeloid malignancies: 6 mg as a single dose for each chemotherapy cycle, given at least 24 hours after cytotoxic chemotherapy.
|
Incompatibility
Incompatible w/ NaCl soln.
|
Special Precautions
Patient w/ sickle cell disease. Not intended for treatment of myelodysplastic syndrome, chronic myelogenous leukaemia and secondary acute myeloid leukaemia (AML). Pregnancy and lactation.
|
Adverse Reactions
Bone or musculoskeletal pain, hypersensitivity reactions (e.g. urticaria, skin rash, angioedema, erythema, flushing, dyspnoea, hypotension, cutaneous vasculitis, SC tissue disorders), splenomegaly, glomerulonephritis, leukocytosis, pulmonary AR (e.g. interstitial pneumonia; pulmonary oedema, infiltrates and fibrosis).
Potentially Fatal: Splenic rupture, resp failure or acute resp distress syndrome, capillary leak syndrome, serious allergic reactions (e.g. anaphylaxis), sickle cell crises (in patients w/ sickle cell disorders). |
Monitoring Parameters
Obtain CBC w/ differential and platelet count prior to and during therapy. Monitor haematocrit regularly.
|
Drug Interactions
Diminished therapeutic effect w/ pegloticase.
|
Lab Interference
May interfere w/ bone imaging studies.
|
Action
Description:
Mechanism of Action: Pegfilgrastim is a covalent conjugate of filgrastim and monomethoxypolyethylene glycol which binds to specific cell surface receptors of haematopoietic cells, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. Pharmacokinetics: Absorption: Time to peak plasma concentration: 16-120 hr. Excretion: Mainly via neutrophil-mediated clearance; serum clearance decreases w/ increasing dose. Half-life: 15-80 hr. |
Storage
Store between 2-8°C. Do not freeze. Protect from light.
|
MIMS Class
|
ATC Classification
L03AA13 - pegfilgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
|
References
Anon. Pegfilgrastim. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/01/2016. Buckingham R (ed). Filgrastim. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/01/2016. McEvoy GK, Snow EK, Miller J et al (eds). Pegfilgrastim. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 04/01/2016. Neulasta Injection (Amgen Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 04/01/2016. Neulasta Injection. U.S. FDA. https://www.fda.gov/. Accessed 04/01/2016.
|